| 18.41 0.16 (0.88%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 21.86 |
1-year : | 25.53 |
| Resists | First : | 18.71 |
Second : | 21.86 |
| Pivot price | 17.25 |
|||
| Supports | First : | 17.08 |
Second : | 16.06 |
| MAs | MA(5) : | 17.29 |
MA(20) : | 17.14 |
| MA(100) : | 16.16  |
MA(250) : | 15.46 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 73.8 |
D(3) : | 50.2 |
| RSI | RSI(14): 62.6 |
|||
| 52-week | High : | 20.72 | Low : | 10.68 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ HCM ] has closed below upper band by 9.9%. Bollinger Bands are 10% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 18.72 - 18.79 | 18.79 - 18.85 |
| Low: | 17.91 - 18 | 18 - 18.07 |
| Close: | 18.28 - 18.39 | 18.39 - 18.5 |
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.
Wed, 24 Apr 2024
HUTCHMED (China) (LON:HCM) shareholders are up 8.2% this past week, but still in the red over the last five years - Yahoo Finance UK
Tue, 23 Apr 2024
HUTCHMED (NASDAQ:HCM) Shares Gap Up to $16.94 - MarketBeat
Tue, 23 Apr 2024
What's Driving HUTCHMED (China) Ltd's Surprising 28% Stock Rally - GuruFocus.com
Mon, 22 Apr 2024
HUTCHMED Announces Key Managerial LTIP Vesting - TipRanks.com - TipRanks
Mon, 22 Apr 2024
HUTCHMED Executives' Incentive Plan Vested - TipRanks.com - TipRanks
Tue, 16 Apr 2024
HUTCHMED (NASDAQ:HCM) Shares Gap Down to $17.66 - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 171 (M) |
| Shares Float | 1,000 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 9.4 (%) |
| Shares Short | 501 (K) |
| Shares Short P.Month | 474 (K) |
| EPS | 0.6 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.86 |
| Profit Margin | 12 % |
| Operating Margin | -30.6 % |
| Return on Assets (ttm) | 0.9 % |
| Return on Equity (ttm) | 14.6 % |
| Qtrly Rev. Growth | 36 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 4.9 |
| EBITDA (p.s.) | 0.15 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 219 (M) |
| Levered Free Cash Flow | 40 (M) |
| PE Ratio | 30.68 |
| PEG Ratio | 0 |
| Price to Book value | 21.4 |
| Price to Sales | 3.75 |
| Price to Cash Flow | 14.33 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|